PerClot® Polysaccharide Hemostatic System is a unique, absorbable powder hemostat that is commercially available in over 35 countries outside of the United States. PerClot is composed of plant starch that is modified to create an adhesive hemostatic powder. It is used as an adjunctive hemostatic device to control bleeding during multiple open and laparoscopic surgical procedures, including gynecologic, general, cardiovascular and urology. PerClot rapidly absorbs water from blood to produce a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.
On June 29, 2021 Baxter International Inc. (NYSE: BAX) acquired certain assets related to the PerClot Polysaccharide Hemostatic System.
A multi-center, randomized controlled clinical trial has been completed of more than 300 patients intended to support an application for U.S. Food and Drug Administration (FDA) clearance. The trial evaluated the safety and efficacy of PerClot in achieving intra-operative hemostasis.
PerClot is available in 1g, 3g, and 5g configurations with applicators to accommodate various surgical procedures including laparoscopic. The system is delivered to the sterile field in a double barrier, sterile pouch and is intended as an absorbable hemostatic system to control bleeding during surgical procedures or following traumatic injuries.
For more information, please contact Baxter International Inc.
PerClot® is manufactured under U.S. Patent No. 8912168.